Andreano JM et al. Menstrual cycle modulation of the relationship between cortisol and long-term memory. . Psychoneuroendocrinology. 2008 Jul’33(6):874-82

Atzeni F et al. In etanercept-treated psoriatic arthritis patients clinical improvement correlated with an increase of serum cortisol relative to other adrenal hormones. Clin Exp Rheumatol. 2008 Jan-Feb;26(1):103-8

Bruehl H et al. A blunted cortisol awakening response and hippocampal atrophy in type 2 diabetes mellitus. . Psychoneuroendocrinology. 2009 Jul;34(6):818-21

Coutinho WF et al. Does binge eating disorder alter cortisol secretion in obese women? Eat Behav. 2007 Jan;8)1):59-64

Cutolo M et al. Circadian rhythms: glucocorticoids and arthritis. Ann NY Acad Sci. 2006 Jun;1069:289-99

Dadoun F et al. Effect of sleep apnea syndrome on the circadian profile of cortisol in obese men. Am J Physiol Endocrinol Metab. 2007 Aug;292(2):E466-74

Dahlgren A et al. Day-to-day variation in saliva cortisol – relation with sleep, stress and self-rated health. Biol Psychol. 2009 Oct;82(2):149-55

Er H et al. Intravitreal cortisone injection for refractory diffuse diabetic macular edema. Ophthalmologica. 2005 Nov-Dec;219(6):394-400

Greaves-Lord K et al. Baseline cortisol measures and developmental pathways of anxiety in eraly adolescence. Acta Psychiatr Scand. 2009 Sep;120(3):178-86

Hafstrom I et al. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 year: an open 2 year continuation study.  Ann Rheum Dis. 2009 Apr;68(4):508-13

Haugeberg G et al. Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis. Results from a randomized placebo-controlled trial. Arch Intern Med. 2005;165:1293-7

Minetto MA et al Changes in awakening cortisol response and midnight salivary cortisol are sensitive markers of strenuous training-induced fatigue. J Appl Biobehav Res 2008 Jan;31(1):16-24

Nakayama Y et al. Cortisol levels and prospective and retrospective memory in humans. Neuro Endocrinol LEtt. 2005 Oct;26(5):599-602

Nater UM et al. Attenuated morning salivary cortisol concentrations in a population-based study of persons with chronic fatigue syndrome and well controls . J Clin Endocrinol Metab. 2008 Mar;93(3):703-9

Osterberg Ket al. Cognitive performance in patients with burnout, in relation to diurnal salivary cortisol. Stress. 2009;12(1):70-81

Petrelluzzi KF et al. Salivary cortisol concentrations, stress and quality of life in women with endometriosis and chronic pelvic pain. Stress. 2008;11(5)390-7

Putman O et al. A single administration of cortisol acutely reduces preconscious attention for fear in anxious young men. Psychoneuroendocrinology. 2007 Aug;32(7):793-802

de Quervain DJ et al. Glucocorticoids and the regulation of memory in health and disease. Front Neuroendocrinol. 2009 Aug;30(3):358-70

Roberts AD et al. Salivary cortisol output before and after cognitive behavioural therapy for chronic fatigue syndrome. J Affect Disord. 2009 May;115(1-2):280-6

Rocco A et al. Inverse correlation between morning plasma cortisol levels and MMPI psychasthenia and depression scale scores in victims of mobbing with adjustment disorders. Neuro Endrocrinol Lett.  2007 Oct;28(5):610-3

Shirtcliff EA et al. Low salivary cortisol levels and externalizing behavior problems in youth. Deb Psycopathol. 2005 Winter;17(1):167-84

Smeets T et al. Memory is differentially affected by stress-induced cortisol elevations and sympathetic activity at consolidation and retrieval. Psychoneuroendocrinology. 2008 Nov;33(10):1378-86

Soravia LM et al. Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci USA. 2006 Apr 4;103(14):5585-90

Souza-Talarico JN et al. Relationship between cortisol levels and memory performance may be modulated by the presence of absence of cognitive impairment: evidence from healthy, elderly mild cognitive impairment and Alzheimer’s disease subjects. Alzheimers Dis 2010Jan;19(3):839-48

Stetler C et al. Blunted cortisol response to awakening in mild to moderate depression: regulatory influences of sleep patterns and social contacts. J Abnorm Psychol. 2005 Nov;114(4):697-705

Tops M et al. Acute cortisol administration reduces subjective fatigue in healthy women. Psychophysiology. 2006 Nov;43(6):653-6

Yehuda R et al. Enhanced effects of cortisol administration on episodic and working memory in aging veteran with PTSD. . Psychoneuroendocrinology.2007 Dec;32(12):258-91


Akishita M et al. Association of plasma dehydroepiandrosterone-sulfate levels with endothelial function in postmenopausal women with coronary risk factors. Hypertens Res. 2008 Jan;31(1):69-74

Alhaj HA et al. Effects of DHEA administration on episodic memory, cortisol and mood in healthy young men: a double-blind, placebo-controlled study. Psychopharmacology (Berl). 2005 Oct 18;1-11

Alkatib AA et al. A systematic review and meta-analysis of randomized placebo-controlled trial of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009 Oct;94(10):3676-81

Bauer ME et al. Stress, glucocorticoids and aging of the immune system. Stress. 2005 Mar;8(1):69-83

Bednarek-Tupikowska G et al. The correlations between endogenous dehydroepiandrosterone sulfate and some atheroschlerosis risk factors in premenopausal women. Med Sci Minot. 2008 Jan;14(10):CR3741

Brignardello E et al. Dehydroepiandrosterone administration counteracts oxidative imbalance and advanced glycation end product formation in type 2 diabetic patients. Diabetes care. 2007 Nov;30(11):2922-7

Cappola AR et al. Trajectories of dehydroepiandrosterone sulfate predict mortality in order older adults: the cardiovascular health study. J Gerontol A Biol Sci Med Sci. 2009 Dec;64(12):1268-74

Dhatariya K et al. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabets. 2005 Mar;54(3):765-9

Enomoto M et al. Serum dehydroepiandrosterone sulfate levels predict longevity in men: 27-year follow-up study in a community-based cohort (Tanushimaru study). J Am Geriatr Soc. 2008 Jun;56(6):994-8

Fukui M et al. Serum dehydroepiandrosterone sulfate concentration and carotid atherosclerosis in men with type 2 diabetes.  Atherosclerosis 2005 Aug;181(2):339-44

Hampl et al. Steroids and thermogenesis. Physiol Res. 2005 May 24

Herman WA et al. Could serum DHEA and DHEAS levels be good risk predictors of metabolic syndrome and osteoporosis in the population of aging men? Pol Merkur Lekarski. 2009 Sep;27(159):197-201

Jankowski CM et al. Effects of DHEA Replacement Therapy on Bone Mineral Density in Older Adults: A Randomized, Controlled Trial. J Clin Endocrinol Metab. 2006 May 30

Jankowski EA et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006 Oct 24;114(17):1829-37

Jian ZW et al. Relationship between dehydroepiandrosterone and arteriosclerosis in premenopausal and postmenopausal women. Nan Fang Yi Ke Da Xue Xue Bao. 2008 Jun;28)6):942-3

Labrie F et al. Is dehydroepiandrosterone a hormone?  J Endocrinol 2005 Nov;187(2):169-96

Maes M et al. Decreased dehydroepiandrosterone sulfate but normal insulin-like growth factor in chronic fatigue syndrome(CFS): relevance for the inflammatory response in CFS. Neuro Endocrinol LEtt. 2005 Oct;26(5):487-92

Martina V et al. Short-term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects.  Clin Endocrinol (Oxf). 2006 Mar;64(3):260-4

Morgan CA 3rd et al. Relationships among plasma dehydroepiandrosterone and dehydroepiandrosteronesulfate, cortisol, symptoms of dissociation, and objective performance in humans exposed to underwater navigation stress. Biol Psychiatry. 2009 Aug 15;66(4):334-40

Nordmark G et al. Effects of dehydroepiandrosterone supplement on health-related qulity of life in glucocorticoid treated females with system lupus erythematosus. Autoimmunity. 2005 Nov;38(7):531-40

Rabijewski M et al. Positive effects of DHEA therapy on insulin resistance and lipids in men with angiographically verified coronary artery heart disease. Prelim study. Endokrynol Pol. 2005;56(6):904-10

Ritsner M et al. Alterations in DHEA metabolism in schizophrenia: Two-month case-control study. Eur Neuropsychopharmacol. 2006 Feb;16(2):137-46

Savastano S et al. Role of dehydroepiandrosterone sulfate levels on body composition after laparoscopic adjustable gastric banding in pre-menopausal morbidly obese women. J Endocrinol. 2005 Jun;28(6):509-15

Schmidt M et al. Inflammation and sex hormone metabolism. Ann N Y Acad Sci. 2006 Jun;1069:236-46

Severi G et al. Circulating steroid hormones and the risk of prostate cancer. Epidemiol Biomarkers PRev. 2006 Jan;15(1):86-91

Shilkaitis A et al. Dehydroepiandrosterone inhibits the progression phase of mammary cardinogensis by inducing cellular senescence via a ;16-dependent but p53-independent mechanism. Breast Cancer Res. 2005;7(6):R1132-40

Tellez N et al. Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone. Mult Scler. 2006 Aug;12(4):487-94

Von Muhlen et al. The Dehydroepiandrosterone and Wellness (DAWN) study: research design and methods. Contemp Clin Trial. 2007 Feb;28(2):153-68

Yang SC et al. Interactive effect of an acute bout of resistance exercise and dehydroepiandrosterone administration on glucose tolerance and serum lipids in middle-aged women. Chin J Physiol. 2005 Mar 31;48(1):23-9


Batur P et al. Menopausal hormone therapy (HT) in patients with breast cancer. Maturitas. 2006 Jan 20;53(2):123-32

Duckles SP et al. Estrogen and Mitochondria: a New Paradigm for Vascular Protection? Molecular Interventions. 6:26-35 (2006)

Fournier A et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005 Apr10;114(3):448-54

Fournier A et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Cancer Res Treat. 2008 Jan;107(1):103-11

Grodstein F et al. The Role of Time since Menopause and Age at Hormone Initiation. Women’s Health J Hormone Therapy and Coronary Heart Disease: 2006 Jan/Feb;15

Klaiber EL et al. A critique of the Women’s Health Initiative hormone therapy study. Fertil Steril. 2005 Dec; 84(6):1589-601

Menon DV et al. Effects of transdermal estrogen replacement therapy on cardiovascular risk factors. Treat Endocrinol. 2006;5(1):37-51

Mishra RG et al. Metabolite ligands of estrogen receptor-beta reduce primate coronary hyperreactivity. Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H295-303

Ouyang P et al. Hormone replacement therapy and the cardiovascular system: lessons learned and unanswered questions. J Am Coll Cardiol. 2006 May 2;47(9):1741-53

Philip KL et al. Greater antiarrhythmic activity of acute 17 beta-estradiol in female than male anaesthetized rats: correlation with Ca(2+) channel blockade. Br J Pharmacol. 2006 Aug 29

Schmidt M et al. Inflammation and sex hormone metabolism. Ann N Y Acad Sci. 2006 Jun;1069:236-46

Schmidt JW et al. Hormone replacement therapy in menopausal women: Past problems and future possibilities. Gynecol Endocrinol. 2006 Oct;22(10):564-77

Tivesten A et al. Circulating Estradiol is an Independent Predictor of Progression of Carotid Artery Intima-Media Thickness in Middle-Aged Men. J Clin Endo & Met. 2006 Nov;91(11):4433-7

Growth Hormone

Andreassen et al. Concentrations of the acute phase reactants high-sensitive C-reactive protein and YKL-40 and of interleukin-6 before and after treatment in patients with acromegalsy and growth hormone deficiency. Clin Edocrinol (Oxf). 2007 Aug 28

Bohdanowicz-Pawlek A et al. Risk factors of cardiovascular disease in GH-dificient adults with hypopituitarism: a preliminary report. Med Sci Monit. 2006 Feb;12(2):CR75-80

Bogarin R et al. Growth hormone treatment and risk of recurrence or progression of brain tumors in children: a review. Childs Nerv Syst. 2009 Jan 14

Branski LK et al. Randomized controlled trial to determine the efficacy of long-term growth hormone treatment in severely burned children . Ann Surg. 2009 Sep 2

Calao A et al. Beginning toend: Cardiovascular implications ofgrowth hormone (GH) deficiency and GH therapy. Growth Horm IGF Res.  2006 May 9

Collier SR et al. Growth hormone responses to varying doses of oral arginine. Horm IGF Res. 2005 Apr;15(2):136-9

Cuatrecasas G et al. Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. BMC Musculoskelet Disord. 2007 Nov 30

Franco C et al. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12 month placebo controlled trial. J Clin Endocrinol Metab. 2005 Mar;90-93):1466-74

Ghigo E et al. Diagnosis of adult GH deficiency. Growth Horm IGF Res. 2008 Feb; 18(1):1-16

Ho KK et al. Regulating of growth hormone sensitivity by sex steroids: implications for therapy. Front Horm Res. 2006;35:115-28

Jenkins PJ et al. Does growth hormone cause cancer? Clin Endocrinol (Oxf). 2006 Feb;64(2):115-21

Johnsen P et al. Insulin-like growth factor (IGF) I,II and IGF Binding Protein-3 and risk of ischemic stroke. J Clin Endcrinol Metab 2005 90:5937-41

Major J et al. Insulin-like growth factor I and cancer mortality in older men. The J of Clin Endocrin & Metab.  2010 Mar;95(3):1054-9

Mitsi AC et al. Early, intracoronary growth hormone administration attenuates ventricular remodeling in a porcine model of myocardial infarction. Growth Horm IGF Res. 2006 Apr;16(2):93-100

Mitsi AC et al. Early selective growth hormone administration may ameliorate left ventricular remodeling after myocardial infarction. Med Hypotheses. 2005;64(3):582-5

Muniyappa R et al. Long-term testosterone supplementation augments overnight growth hormone secretion in health older men. Am J Physiol Endocrinol Metab. 2007

Popovic V et al. Hypopituitarism following traumatic brain injury. Growth Horm IGF Res. 2005 Jun;15(3):177-84

Sattler F et al. Testosterone threshold levels and lean tissue mass target needed to enhance skeletal muscle strength and function The HORMA Trial.  J Gerontol A Biol Sci Med Sci. 2010 Nov 8

Schernhammer ES et al. Insulin-like growth factor-I, its binding proteins (IGF-BP1 and IGF-BP3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer. 2006 Jun;13(2):583-92

Stockholm K et al. Mortality and GH deficiency: a nationwide study. Eur J of Endocrin. 2007;(157):9-18

Strassberger C et al.  How robust are laboratory measures of growth hormone status? Hormone Res 2005;(64):1-5

Thum T et al. Growth hormone treatment improves markers of systemic nitric oxide bioavalability via insulin-like growth factor I. J Clin Endocrinol Metab. 2007 Aug 28

Van Dam PS et al. Somatropin therapy and cognitive function in adults with growth hormone deficiency: a critical review. Treat Endocrinol. 2006;5(3):159-70


Carretero, M et al. Long-term melatonin administration protects brain mitochondria from aging. J of Pineal Res. 2009 Sep 47(2):192-200

Cervantes, M et al. Melatonin and ischemia-reperfusion injury of the brain. J Pineal Res 2008 Aug;45(1):1-7

Dominguez-Rodriguez A et al. Prognostic value of nocturnal melatonin levels as a novel marker in patients with ST-segment elevation of myocardial infarction. Am J Cardiol 2006 Apr 15;97(8):1162-4

Dominguez-Rodriguez A et al. A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an adjunct in patients with acute myocardial infarction treated with angioplasty (MARIA) trial: study design and rationale. Comtep Clin Trials 2007 Jul’28(4):532-9

Domingues-Rodriquez A et al. Clinical aspects of melatonin in the acute coronary syndrome. Curr Vasc Pharmacol. 2009 Jul;7(3):367-73.

Flynn-Evans EE et al. Total visual blindness is protective against breast cancer. Cancer Causes Control. 2009 Aug 1

Lenoir V et al. Preventive and curative effect of melatonin on mammary carcinogensis induced by dimethylbenz[a]anthracene in the female Sprague-Dawley rat.  Breast Cancer Res. 2005;7(4):R470-6.

Li JH et al. Melatonin reduces inflammatory injury through inhibiting NF-kappa B activation in rats with colitis. Mediators Inflamm. 2005 Aug 31;2005(4):

Mills Edward et al. Melatonin the in the treatment of cancer: a systemic research review of randomized controlled trials and meta-analysis. J of Pineal Res. 2005 Nov;39(4):360-6

Peres MF et al. Potential use of melatonin in migraine and other headache disorders. Expert Opin Investig Drugs. 2006 Apr;15(4):367-75

Reiter RJ et al. When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp Biol Med (Maywood). 2005 Feb; 230(2):104-17

Samantaray S et al. Therapeutic potential of melatonin in traumatic central nervous system injury. Minim Rev J of Pineal Res. 47(2):134-42

Simko F et al. Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment. J of Pineal Res. 2009 Sep;47(2):127-33

Veneroso C et al. Melatonin reduced cardiac inflammatory injury induced by acute exercise. J of Pineal Res 2009 Sep;47(2):184-91


Marx CE et al. Proof of concept trial with the neurosteroid prenenolone targeting cognitive and negative symptoms in schizophrenia. . Psychoneuroendocrinology. 2009 July;34(8):1885-903


Batur P et al. Menopausal hormone therapy (HT) in patients with breast cancer. Maturitas. 2006 Jan 20;53(2):123-32
Blanchette S et al. Circulating progesterone and obesity in men. Horm Metab Res. 2006 May;38(5):330-5

Campagnoli C et al. Pregnancy progesterone and prgestins in relation to breast cancer risk. Journal of Steroid Biochemistry and Molecular Biology 97(2005,Dec)441-50

Fournier A et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005 Apr10;114(3):448-54

Fournier A et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Cancer Res treat. 2008 Jan;107(1):103-11

Grodstein F et al. The Role of Time since Menopause and Age at Hormone Initiation. Women’s Health J Hormone Therapy and Coronary Heart Disease: 2006 Jan/Feb;15

Klaiber EL et al. A critique of the Women’s Health Initiative hormone therapy study. Fertil Steril. 2005 Dec; 84(6):1589-601

Schmidt M et al. Inflammation and sex hormone metabolism. Ann N Y Acad Sci. 2006 Jun;1069:236-46

Schmidt JW et al. Hormone replacement therapy in menopausal women: Past problems and future possibilities. Gynecol Endocrinol. 2006 Oct;22(10):564-77


Argarwal PK et al. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005 feb;183(2):533-6

Arnlov J et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006 Aug1;145(3):176-84

Bhasin S et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006 Jun;91(6):1995-2010

Caminiti G et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009 Sep 1;54(10):919-27

Cardinale M et al. Is testosterone influencing explosive performance? J Strength Cond Res. 2006 Feb;20(1):103-7

Caretta N et al. Erectile dysfunction in aging men: testosterone role in therapeutic protocols. J Endocrinol Invest. 2005; 28(22 Suppl Proceedings):108-11

Davis SR et al. Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas. 2008 Sept-Oct;61(1-2):17-26

Davison S et al. Phamacokinetics and acute safety of inhaled testosterone in postmenopausal women.  J Clin Pharmacol. 2005 Feb;45(2):177-84

Debing E et al. Endogenous sex hormone levels in postmenopausal women undergoing carotid artery endarterectomy. Eur J Endocrinol. 2007 Jun;156(6):687-93

Dolan SE et al. Effects of weight, body composition, and testosterone on bone mineral density in HIV-infected women. J Acquir Immune Defic Syndr. 2007 Jun1;45(2)161-7

Edinger KL et al. Testosterone’s anti-anxiety and analgesic effects may be due in part to actions of its 5 alpha-reduced metabolites in the hippocampus. Psychoneuroendocrinology. 2005 Jun;30(5):418-30

El-Sakka AI et al. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement. J Sex Med. 2005 Mar;2(2):235-40

Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies Endogenous Hormones and Prostate Cancer Collaborative Group. J Natl Cancer Inst 2008 100:170-183

Fink B et al. The 2nd-4th digit ratio (2D:4D) and neck circumference: implications for risk factors in coronary artery disease. Int J Obes (Lond). 2006 Apr;30

FLoter A et al. Effects of combined estrogen/testosterone therapy on bone and body composition in oophorectomized women. Gynecol Endocrinol. 2005 Mar;20(3):155-60

Gould DC et al. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer? Prostate Cancer Prostatic Dis 2006;9(1):14-8

Habib FK et al. Seronoa repens (Permixon) inhibits the 5 alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer. 2005 Mar 20;114(2):190-4

Hermans EJ et al. A single administration of testosterone reduces fear-potentiated startle in humans. Biol Psychiatry. 2006 May1;59(9):872-4

Iczkowski, K et al The Dual 5 alpha reductase inhibitor dutatsteride induces atrophic changes and decreases cancer volume in the human prostate. Urology 65:76-82, 2005

Jankowska EA. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA. 2009 May 13;301(18):1892-901

Khatibi A et al. Could androgens protect middle-aged women from cardiovascular events? A population-based study of Swedish women: The Women’s Health in the Lund Area (WHILA) Study. Climacteric. 2007 Oct;10(5)L386-92

Keogh E. Can a sexually dimorphic index of prenatal hormonal exposure be used to examine cold pressor pain perception in men and women? Eur J Pain. 2006 Apr 4

Khaw KT et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men. Circulation. 2007;116:2694-2701

Kupelian V et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in non-obese men. J Clin Endocrinol Metabl. 2006 Mar; 91(3):843-50

Lam KS. Serum total and bioavailable testosterone levels, central obesity, and muscle strength changes with aging in health Chinese men. J Am Geriatr Soc. 2008 Jul;67(7):1286-91

Lunenfeld B Endocrinology of the aging male. Minerva Ginecol. 2006 Apr;58(2):153-70

Ly LP et al. Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays. Eur J endocrinol. 2005 Mar;152(3):471-8

Maggio M et al. Correlation between testosterone and the inflammatory marker soluble interleukin-6 (sIL-6r) in older men. J Clin Endocrinol Metabl. 2005 Nov 1

Makinen J et al. Increased carotid atherosclerosis in andropausal middle-aged men. J AmColl Cardiol. 2005 May 17;45(10)

Malkin CJ et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial.  Eur Heart J 2005 Aug 10

Marks LS et al. Effect of testosterone replacement therapy on prostate tissue in men with late=onset hypogonadism: a randomized controlled trial. JAMA 2006 Nov 15; 296(19):2369-71

Moffat SD et al. Long-term measure of free testosterone predict regional cerebral blood flow patterns in elderly men. Neurobiol Aging. 2006 May 11

Morales A. Monitoring androgen replacement therapy: testosterone and prostate safety. J Endocrinol Invest. 2005;28(3 Suppl):122-7

Morgentaler A. Testosterone and Prostate Cancer: An Historical Perspective on a Modern Myth. Eur Urol. 2006 Jul 26

Morgentaler A. Testosterone replacement therapy and prostate risks: where’s the beef? Can J Urol. 2006 Feb;13 Suppl 1:40-3

Morgentaler A. Guideline for Male Testosterone therapy.  A clinician’s perspective. J Clin Endo Metab. 92(2)416-17, 2007

Morgentaler A et al. Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer . J Sex Med. 2009 Feb; 6(2):574-7

Muniyappa R et al. Long-Term Testosterone Supplementation Augments Overnight Growth Hormone Secretion in Health Older Men. Am J Physiol Endocrinol Metab. 2007

Pantuck AJ et al. Phase II Study of Pomegrantate Juice for Men with Risisng Prostate-Specific Antigen following Surgery or Radiation for Prostate Cancer . Clin Cancer Res. 2006 Jul 1;12(13):4018-4026

Phillips GB. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J CLin Endocrinol Metab. 2005 May;90(5):2708-11

Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007 Feb 1;109(3):536-41

Schmidt M et al. Androgen conversion in osteoarthritis and rheumatoid arthritis synoviocytes – androstenedione and testosterone inhibit estrogen formation and favor production of more potent 5 aplapha-reduced androgens. Arthritis Res Ther. 2005;7(5):R938-48

Shakir YA et al. Do sex hormones influence features of the metabolic syndrome in middle-aged women? A population-based study of Swedish womn: The Women’s Health in the Lund Area (WHILA) Study. Fertil Steril. 2007 Jul;88(1):163-71

Shores MM et al. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006 Aug 14; 116(15):1660-5

Singh AB et al. Pharmacokinetics of a testosterone gel in healthy postmenopausal women. J Clin Endocrinol Metab. 2006 Jan;91(1):136-44

Sinha-Hikim I et al. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. J Clin Endocrinol Metab. 2006 Aug;91(8):3024-33

Svartberg J. Epidemiology: testosterone and the metabolic syndrome. Int J Impot Res. 2006 Jul 20

Travison TG et al. A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Metabl. 2006 Oct 24

Tsujimura A et al. Treatment with human chorionic gonadotropin for PADAM: preliminary report. Aging Male. 2005 Sep-Dec;8(3-4):175-9

Turhan S et al. The association between androgen levels and premature coronary artery disease in men. Coron Artery Dis. 2007 May;18(3):159-62

Van Geel TA et al. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle mass, muscle strength and bone mineral density in postmenopausal women: a cross-sectional study. Eur J Endocrinol. 2009 Apr;160(4):681-7

Van Honk J et al. Testosterone reduces unconscious fear but not consciously experienced anxiety: implications for the disorders of fear and anxiety. Biol Psychiatry. 2005 Aug1;58(3):218-25

Vigna GB et al. Testosterone replacement, cardiovascular system and risk factors in the aging male. J Endocrinol Invest. 2005; 28(11 Suppl Proceedings):69-74

Yeap BB et al. Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men.  The Health in Men Study. Eur J Endocrinol. 2009 Aug 18

Yeap BB et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men . J Cin Endocrinol Metab. 2009 Jul;94(7)2353-9

Yeap BB et al. Serum testosterone levels correlate with hemoglobin in middle-aged men and older men. Intern Med J. 2008 Aug 16

Yeap BB et al. Testosterone and ill-health in aging men. Nat Clin Pract Endocrinol Metab. 2009 Feb;5(2):113-21

Yeap BB et al. Are declining testosterone levels a major risk factor for ill-health in aging men? Int J Impot Res. 2009 Jan-Feb;21(1)24-36

Yeap BB et al Healthier lifestyle predicts higher circulating testosterone in older men: The Health in Men Study. Clin Endocrinol (Oxf). 2009 Mar; 70(3):455-63

Yeap BB et al. Luteinizing hormone levels are positively correlated  with plasma amyloid-beta protein levels in elderly men. J Alzheimers Dis. 2008 Jun;14(2):201-8

Yeap BB et al. Lower sex hormone-binding globulin is more strongly associated with metabolic syndrome than lower testosterone in older men: The Health in Men Study. Eur J Endocrinol. 2008 Jun;158(6):785-92

Yeap BB et al. Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older men. Arch Gen Psychiatry. 2008 Mar;65(3):283-9

Yeap BB et al. Higher serum free testosterone is associated with better cognitive function in older men, while total testosterone is not. The Health in Men Study. Clin Endocrinol (Oxf). 2008 Mar;68(3):404-12

Yeap BB et al. In men older than 70 years, total testosterone remains stable while free testosterone declines with age. The Health in Men Study. Eur J Endocrinol. 2007 May;156(5):585-9


Aksoy DY et al.  Effects of prophylactic thyroid hormone replacement in euthyroid Hashimoto’s thyroiditis.  Endocr J  2005 June; 52(3):337-43

Antonelli A et al. High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis

Constant EL et al.  Anxiety and depression, attention, and executive functions in hypothyroidism. J Int Neuropsychol Soc. 2005 Sep;11(5):535-44

Danzi S et al.  Potential uses of T3 in the treatment of human disease. Clin Cornerstone. 2005; 7 Suppl 2:S9-15

Dorr M et al. Cardiovascular morbidity and mortality in thyroid dysfunction. Minerva Endocrinol. 2005 Dec;30(4):199-216

El-Shaikh KA  Recovery of age-dependent immunological deterioration in old mice by thyroxine treatment.  J Anim Physio Anim Nutr (Berl). 2006 Jun; 90(5-6):244-54

Erdam TY et al. Plasma viscosity, an early cardiovascular risk factor in women with subclinical hypothyroidism. Clin Hemorheal Microcirc. 2008;38(4):219-25

Escobar-Morreale HF et al.  Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyxoine alone.  Ann Intern Med.  2005 Mar 15; 142(6):412-24

Fernandez-Real JM et al. Thyroid function is intrinsically linked to insulin sensitivity and endothelium-dependent vasodilation in healthy eurthyroid subjects.  J Clin Endocrinol Metab.  2006 Jun 27

Harel L et al. Increased prevalence of antithyroid antibodies and subclinical hypothyroidism in children with juvenile idiopathic arthritis.  J Rheumatol. 2006 Jan;33(1):164-6

Jha A et al.  Thyroxine replacement therapy reverses sleep-disordered breathing in patient with primary hypothyroidism. Sleep Med. 2006 Jan;7(1):55-61

Kileinikov DV et al. Pathogenesis of arterial hypertension in patients with primary hypothyroidism. Klin Med (Mosk). 2009:87(5):30-2

Kim SK et al.  Regression of the increased common carotid artery-intima media thickness in subclinical hypothyroidism after thyroid hormone replacement. Endocr J 2009 Dec;56(6):753-8

Knudsen N et al.  Small difference in thyroid function may be important for body mass index and the occurrence of obesity in the population.  J Clin Endocrinol Metab.  2005 Jul; 90(7)4019-24

Kotsis V et al. Hypertension and hypothyroidism: results from an ambulatory blood pressure monitoring study. J Hypertens. 2007 May;25(5):993-9

Kozdag G et al. Relation between free triiodothyronine/free thyroxine ratio, echocardiographic parameters and mortality in dilated cardiomyopathy. Eur J Heart Fail. 2005 Jan;7(1):113-8

Kuijpens JL et al.  Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid 2005 Nov;15(11):1253-9

Mainenti MR et al.  Effect of levothyroxine replacement on exercise performance in subclinical hypothyroidism. Endrocinol Invest. 2009 May;32(5):470-3

Mayer O Jr et al.  Hypothyroidism in coronary heart disease and its relation to selected risk factors. Vasc Health Risk Manag. 2006;2(4):499-506

Meeker JD et al. Relationships between serum hormone levels and semen quality among men from an infertility clinic.  J Androl. 2007 May-Jun;28(3):397-406

Miller KH et al.  Verbal memory retrieval deficits associated with untreated hypothyroidism.  J Neuropsychiatry Clin Neurosci. 2007 Spring;19(2):132-6

Misiolek M et al. Sleep apnea syndrome and snoring in patient with hypothyroidism with relation to overweight. J Physiol Pharmacol. 2007 Mar;58 Suppl 1:77-85

Nanda N et al.  Association of thyroid stimulating hormone and coronary lipid risk factors with lipid peroxidation in hypothyroidism.  Clin Chem Lab Med.  2008; 46(5):674-9

Owen PJ et al. Subclinical hypothyroidism, arterial stiffness, and myocardial reserve. J Clin Endocrinol Metab. 2006 Jun;91(6):2126-32

Pesic M et al. Cardiovascular risk factors in patients with subclinical hypothyroidism.  Vojnosanit Pregl. 2007 Nov;64(11):749-52

Pingitore A et al. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med. 2005 Feb;118(2):132-6

Raterman HG et al. Rheumatoid arthritis is associated with a high prevalence of hypothyroidism that amplifies its cardiovascular risk. Ann Rheum Dis. 2008 Feb;67(2):229-32

Razvi S et al.  The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial.  J Clin Endocrinol Metab.  2007 May;92(5):1715-23

Razvi S et al.  The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: Reanalysis of the Whickham Survey Cohort. J Clin Endocrinol Metab. 2010 Apr;95(4):1734-40

Razvi S et al. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a metaanalysis.  J Clin Endocrinol Metab. 2008 Aug;93(8):2998-3007

Rodondi N et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular eent, and death.  Arch Intern Med. 2005 Nov 28;165(21):2460-6

Rotondi M et al. Raised serum TSH levels in patients with morbid obesity: is it enough to diagnose subclinical hypothyroidism? Eur J Endocrinol. 2009 Mar;160(3):1135-8

Samuels MH et al.  Health status, mood, and cognition in experimentally induced subclinical hypothyroidism.  J Clin Endocrinol Metab.  2007 Jul;92(7):2545-51

Saravanan P et al.  Partial substitution of thyroxine (T4) with triiodothyronine in patients on T4 replacement therapy: results of a large community-based randomized controlled trail.  J Clin Endocrinol Metab. 2005 Feb;90(2):805-12

Surk MI et al.  The thyrotropin reference range should remain unchanged. J Clin Endrocinol Metab. 2005 Sep; 90(9):5489-96

Turhan S et al. Plasma homocysteine concentrations and serum lipid profile as atherosclerotic risk factors in subclinical hypothyroidism. Ann Saudi Med. 2008 Mar-Apr;28(2):96-101

Ursella S et al.  Amiodarone-induced thyroid dysfunction in clinical practice. N. Eur Rev Med Pharmacol Sci. 2006 Sep-Oct;10(5):269-78

Velkoska NV et al. Dyslipidaemia and hypertension in patients with subclinical hypothyroidism. Prilozi. 2009 Dec;30(2):93-102

Veronelli A et al  Sexual dysfunction is frequent in premenopausal women with diabetes, obesity, and hypothyroidism, and correlates with markers of increased cardiovascular risk.  A preliminary report.  J Sex Med. 2009 Jun;6(6):1561-8

Walsh JP et al.  Small changes in thyroxine dosage do not produce measurable change in hypothyroid symptoms, well-being or quality of life: results of a double blind randomized clinical trial.  J Clin Endocrinol Metab. 2006 May 2

Wartofsky L et al.  Overt and ‘subclinical’ hypothyroidism in women. Obestet Gynecol Surv.  2006 Aug; 61(8):535-42

Wartofsky L and Dickey RA  The evidence for a narrower thyroptropin reference range is compelling.  J Clin Endocrinol Metab. 2005 Sep; 90(9):5483-8

Zoncu S et al.  Cardiac function in borderline hypothyroidism: a study by pulsed wave tissue Doppler imaging. Eur J Endocrinol 2005 Apr;152(4):527-33

For more citations with abstracts:
Rothenberg R, Hart K  Hormone Optimization in Preventive/Regenerative Medicine 2009